<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124388">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01916473</url>
  </required_header>
  <id_info>
    <org_study_id>M-20/23-02-2010</org_study_id>
    <nct_id>NCT01916473</nct_id>
  </id_info>
  <brief_title>Epidural Versus Continuous Wound Ropivacaine Infusion Analgesia</brief_title>
  <official_title>Epidural Versus Continuous Wound Ropivacaine Infusion: Effect on Acute and Chronic Pain After Myomectomy or Total Abdominal Hysterectomy. A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Athens</source>
  <oversight_info>
    <authority>Greece: National Organization of Medicines</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Hypothesis: The analgesic requirements and pain scores postoperatively differ between
      the epidural and continuous wound infusion techniques.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The analgesic requirements and pain scores postoperatively  differ between the epidural and
      continuous wound infusion techniques, in patients undergoing myomectomy or hysterectomy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Postoperative morphine consumption</measure>
    <time_frame>2 hours postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative morphine consumption</measure>
    <time_frame>4 hours postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative morphine consumption</measure>
    <time_frame>8 hours postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative morphine consumption</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative morphine consumption</measure>
    <time_frame>48 hours postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative morphine consumption</measure>
    <time_frame>72 hours postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative morphine consumption</measure>
    <time_frame>3 months postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative morphine consumption</measure>
    <time_frame>6 months postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>pain scores</measure>
    <time_frame>2 hours postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain scores</measure>
    <time_frame>4 hours postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain scores</measure>
    <time_frame>8 hours postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain scores</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain scores</measure>
    <time_frame>48 hours postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain scores</measure>
    <time_frame>72 hours postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain scores</measure>
    <time_frame>3 months postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain scores</measure>
    <time_frame>6 months postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Postoperative Analgesia</condition>
  <arm_group>
    <arm_group_label>Epidural analgesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epidural analgesia is provided with ropvacaine 0.2% given 6 hourly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous wound infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The continuous wound infusion consists of 0.376% ropivacaine infusion in the wound area at a rate 2 ml per hour.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Epidural analgesia</intervention_name>
    <description>Epidural analgesia is provided with ropvacaine 0.2% given 6 hourly</description>
    <arm_group_label>Epidural analgesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Continuous wound infusion</intervention_name>
    <description>Continuous wound infusion via catheter</description>
    <arm_group_label>Continuous wound infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients ASA I-II scheduled for abdominal hysterectomy or myomectomy -

        Exclusion Criteria:

        Age older than 60 and younger than 25 years, body weight exceeding the 30% of the ideal,
        consumption of analgesics, sedatives, anxiolytics, antidepressants, calcium channel
        blockers, CNS disease or insulin dependent diabetes

        -
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Argyro Fassoulaki, MD,PhD, DEAA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Athens</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aretaieio Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 1, 2013</lastchanged_date>
  <firstreceived_date>July 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Athens</investigator_affiliation>
    <investigator_full_name>Argyro Fassoulaki</investigator_full_name>
    <investigator_title>Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Epidural analgesia</keyword>
  <keyword>continuous wound infusion</keyword>
  <keyword>ropivacaine</keyword>
  <keyword>total abdominal hysterectomy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
